Literature DB >> 15059877

Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium.

Alexander Yu Nikitin1, Ana Alcaraz, Miriam R Anver, Roderick T Bronson, Robert D Cardiff, Darlene Dixon, Armando E Fraire, Edward W Gabrielson, William T Gunning, Diana C Haines, Matthew H Kaufman, R Ilona Linnoila, Robert R Maronpot, Alan S Rabson, Robert L Reddick, Sabine Rehm, Nora Rozengurt, Hildegard M Schuller, Elena N Shmidt, William D Travis, Jerrold M Ward, Tyler Jacks.   

Abstract

Rapid advances in generating new mouse genetic models for lung neoplasia provide a continuous challenge for pathologists and investigators. Frequently, phenotypes of new models either have no precedents or are arbitrarily attributed according to incongruent human and mouse classifications. Thus, comparative characterization and validation of novel models can be difficult. To address these issues, a series of discussions was initiated by a panel of human, veterinary, and experimental pathologists during the Mouse Models of Human Cancers Consortium (NIH/National Cancer Institute) workshop on mouse models of lung cancer held in Boston on June 20-22, 2001. The panel performed a comparative evaluation of 78 cases of mouse and human lung proliferative lesions, and recommended development of a new practical classification scheme that would (a) allow easier comparison between human and mouse lung neoplasms, (b) accommodate newly emerging mouse neoplasms, and (c) address the interpretation of benign and preinvasive lesions of the mouse lung. Subsequent discussions with additional experts in pulmonary pathology resulted in the current proposal of a new classification. It is anticipated that this classification, as well as the complementary digital atlas of virtual histological slides, will help investigators and pathologists in their characterization of new mouse models, as well as stimulate further research aimed at a better understanding of proliferative lesions of the lung.

Entities:  

Mesh:

Year:  2004        PMID: 15059877     DOI: 10.1158/0008-5472.can-03-3376

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  159 in total

1.  Enhanced inhibition of lung adenocarcinoma by combinatorial treatment with indole-3-carbinol and silibinin in A/J mice.

Authors:  Abaineh Dagne; Tamene Melkamu; Melissa M Schutten; Xuemin Qian; Pramod Upadhyaya; Xianghua Luo; Fekadu Kassie
Journal:  Carcinogenesis       Date:  2011-01-27       Impact factor: 4.944

2.  Differential transcriptomic analysis of spontaneous lung tumors in B6C3F1 mice: comparison to human non-small cell lung cancer.

Authors:  Arun R Pandiri; Robert C Sills; Vincent Ziglioli; Thai-Vu T Ton; Hue-Hua L Hong; Stephanie A Lahousse; Kevin E Gerrish; Scott S Auerbach; Keith R Shockley; Pierre R Bushel; Shyamal D Peddada; Mark J Hoenerhoff
Journal:  Toxicol Pathol       Date:  2012-06-11       Impact factor: 1.902

3.  Multiphoton microscopy as a diagnostic imaging modality for lung cancer.

Authors:  Ina Pavlova; Kelly R Hume; Stephanie A Yazinski; Rachel M Peters; Robert S Weiss; Watt W Webb
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2010-01-24

Review 4.  Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence.

Authors:  Silvio De Flora; Gancho Ganchev; Marietta Iltcheva; Sebastiano La Maestra; Rosanna T Micale; Vernon E Steele; Roumen Balansky
Journal:  Trends Pharmacol Sci       Date:  2015-12-23       Impact factor: 14.819

Review 5.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

6.  Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice.

Authors:  Chinthalapally V Rao; Jagan Mohan R Patlolla; Li Qian; Yuting Zhang; Misty Brewer; Altaf Mohammed; Dhimant Desai; Shantu Amin; Stan Lightfoot; Levy Kopelovich
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

7.  Opposing effects of bortezomib-induced nuclear factor-κB inhibition on chemical lung carcinogenesis.

Authors:  Sophia P Karabela; Ioannis Psallidas; Taylor P Sherrill; Chrysoula A Kairi; Rinat Zaynagetdinov; Dong-Sheng Cheng; Spyridoula Vassiliou; Frank McMahon; Linda A Gleaves; Wei Han; Ioannis Stathopoulos; Spyros G Zakynthinos; Fiona E Yull; Charis Roussos; Ioannis Kalomenidis; Timothy S Blackwell; Georgios T Stathopoulos
Journal:  Carcinogenesis       Date:  2012-01-27       Impact factor: 4.944

8.  Lipopolysaccharide enhances mouse lung tumorigenesis: a model for inflammation-driven lung cancer.

Authors:  T Melkamu; X Qian; P Upadhyaya; M G O'Sullivan; F Kassie
Journal:  Vet Pathol       Date:  2013-02-04       Impact factor: 2.221

9.  Pathology Principles and Practices for Analysis of Animal Models.

Authors:  Sue E Knoblaugh; Tobias M Hohl; Krista M D La Perle
Journal:  ILAR J       Date:  2018-12-01

10.  Prenatal stress enhances NNK-induced lung tumors in A/J mice.

Authors:  Tomoaki Ito; Harumi Saeki; Xin Guo; Polina Sysa-Shah; Jonathan Coulter; Kellie L K Tamashiro; Richard S Lee; Hajime Orita; Koichi Sato; Shun Ishiyama; Alicia Hulbert; William E Smith; Lisa A Peterson; Malcolm V Brock; Kathleen L Gabrielson
Journal:  Carcinogenesis       Date:  2020-12-31       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.